Drug repurposing for Chagas disease: *In vitro* assessment of nimesulide against *Trypanosoma cruzi* and insights on its mechanisms of action

Joana D'Arc S. Trindade¹, Célio Geraldo Freire-de-Lima², Suzana Côrte-Real³, Debora Decote-Ricardo⁴*, Marco Edilson Freire de LimaID¹*

1 Instituto de Química, Departamento de Química Orgânica, Universidade Federal Rural do Rio de Janeiro, Seropédica, Rio de Janeiro, Brazil, 2 Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Ilha do Fundão, Rio de Janeiro, Brazil, 3 Instituto Oswaldo Cruz/Fiocruz, Laboratório de Biologia Estrutural, Rio de Janeiro, Brazil, 4 Instituto de Veterinária, Departamento de Microbiologia e Imunologia Veterinária, Universidade Federal Rural do Rio de Janeiro, Seropédica, Rio de Janeiro, Brazil

* marcoedilson@gmail.com (MEFL); decotericardo@ufrrj.br (DDR)

Abstract

Chagas disease is a neglected illness caused by *Trypanosoma cruzi* and its treatment is done only with two drugs, nifurtimox and benznidazole. However, both drugs are ineffective in the chronic phase, in addition to causing serious side effects. This context of therapeutic limitation justifies the continuous research for alternative drugs. Here, we study the *in vitro* trypanocidal effects of the non-steroidal anti-inflammatory drug nimesulide, a molecule that has in its chemical structure a toxicophoric nitroaromatic group (NO₂). The set of results obtained in this work highlights the potential for repurposing nimesulide in the treatment of this disease that affects millions of people around the world.

Introduction

Chagas disease is one of the 17 neglected tropical diseases (NTDs) listed by the World Health Organization, with 6 to 7 million people infected worldwide,¹ being related to underdevelopment and poverty [1]. However, in recent decades the spread of this parasitic infection has been reported to other regions due to climate changes, such as some countries in Europe and also in the United States, where different species of insect vectors infected by *T. cruzi* were found [2, 3]. The treatment of the disease in its acute phase is made only by two drugs benznidazole (BZN) (¹) and nifurtimox (NFX) (²) (Fig 1A). These drugs have several side effects such as anorexia, weight loss, psychic changes, and others [4]. These therapeutic limitations to treat the infected patients point to the need to develop new alternatives for the treatment of this infectious disease. The growing understanding of the pathophysiology of Chagas disease, coupled with important international collaborations involving academia, industry and governments, may culminate in the development of more effective chemotherapeutic agents, with the
potential to remove Chagas disease from the classification of a neglected tropical disease, mainly bringing new hope for the treatment of chronic chagasic patients [5].

The discovery of a new drug is an important achievement and traverses a long conventional path of research, from the identification of the molecular target to its registration and manufacture. The process can last from 10 to 17 years with a high cost involved [6]. Another equally relevant strategy shortens this time by implying new studies for an already known drug. Successful research results in its reuse for a different therapeutic action, proving to be more advantageous in terms of cost as well. Both approaches are important for identifying new trypanocidal compounds. However, finding a treatment faster and at a lower cost for neglected parasitic diseases is a differential that should not be overlooked. Currently, the repurposing approach has been facilitated by the availability of extensive drug library and by advances in genomics and bioinformatics [6].

Studies on nitroheterocycles drugs have advanced and may lead to an understanding of the mechanisms of antiparasitic action of these compounds [7]. It is well known that Non-Steroidal Anti-Inflammatory Agents (NSAIDs), such as nimesulide (NIM) (3, Fig 1B), are inhibitors of eicosanoids biosynthesis, lipid mediators with an important role in the mechanism of T. cruzi infection [8]. Our group had already characterized the modulation of COX-2 as a potential biochemical target for Chagas chemotherapy [9]. The fact that both nimesulide and benznidazole have a nitroaromatic group, known to be toxophoric to T. cruzi, is another relevant point that stimulated us in this study. It is not the first time nimesulide has been evaluated for another therapeutic application other than anti-inflammatory. This drug has already been tested, for example, against the growth of cancer cells [10, 11] and as anti-diabetic [12]. From the data presented, we have understood that the study of the toxic activity of nimesulide against T. cruzi could shed light on the potential application of this anti-inflammatory drug in the treatment of chagasic patients. Recent reports have highlighted the dangers of co-infection of chagasic patients with SARS-CoV-2, due to the heart being one of the most affected organs in patients with COVID-19 [13]. The fact that nimesulide is an anti-inflammatory drug makes this study even more relevant, since one of the problems associated with the chronic phase of Chagas disease is the development of myocarditis, which can lead to heart failure [14].

A widely used analysis technique for identifying cell damage caused by chemical agents is transmission electron microscopy (TEM). In this study, we sought to assess the ultrastructural effects on parasites after treatment with nitroaromatic nimesulide, comparing with the information available in the literature.

Although the ultrastructural effects caused on the parasite’s organelles by drug treatments are useful in the investigation of possible targets and possible mechanisms of action of these potential chemotherapeutic compounds [15–17] the literature states that with respect to T. cruzi there is still insufficient data on the exact path of cell death caused by different molecular
agents, with evidence of death due to multiple factors. For example, changes in chromatin organization, presence of cytosolic myelin figures and formation of autophagosomal bodies, suggest an autophagic death process. However, it is possible to form bubbles in the membrane and changes in chromatin, indicating a possible apoptotic path. Other times, there is a rupture of the plasma membrane, which is related to death by necrosis. In other words, a variety of alterations can be observed, leading to the occurrence of more than one death path, when T. cruzi cells are challenged by different drugs [17, 18].

Material and methods

Chemistry

The equipment used in the characterizations and determination of purity grades of compounds can be found in S1 Text.

Extraction of nimesulide (3) from commercially available medicines. Nimesulide was extracted from tablets of medicines obtained on the market. The acid-base extraction was carried out according to the methodology described by Gonsalves et al. [19]. The white solid obtained was recrystallized twice from ethanol furnishing 0.9 g (90% yield) of highly pure nimesulide (3) [20, 21].

The chemoselective reduction of the nitro group of nimesulide. As shown in Fig 1B, to evaluate the role of nitroaromatic moiety of nimesulide structure, the aniline (4) prepared from nimesulide was obtained as described by Maia et al. [22], using metallic iron in presence of aqueous ammonium chloride and ethanol reagent. The aniline (4) (199 mg; 65% yield) was obtained as a white crystalline solid [21, 23].

The two products obtained were fully characterized through their melting points and spectra data (NMR \(^1H\), \(^13C\), and mass spectra) which are in full agreement with data previously described in the literature [21–23]. All data used in the characterization and determination of the degree of purity of the compounds (3) and (4) can be found in S1–S6 Figs; S1 and S2 Tables.

For the preparation of the solutions of nimesulide, reduced nimesulide and benznidazole, a stock solution of 30 mM of each was prepared using DMSO. The final concentration of drugs in each well was adjusted to 35 \(\mu\)M. The final concentration of DMSO in was 0.12%.

Biological assessments

Animals and ethics statement. BALB/c mice of both sexes, aged 6–8 weeks, were obtained from the Veterinary Institute of the Federal Rural University of Rio de Janeiro, and kept in micro-isolators with food and water ad libitum. This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals, from the National Institutes of Health (United States). The protocol was approved by the Animal Experimentation Ethics Committee of the Veterinary Institute of the Federal Rural University of Rio de Janeiro (CEUA-IV, Authorization Number: 8819010217) and every effort was made to minimize animal suffering. All animal work was performed in accordance with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and regulations.

Parasites. Trypomastigote forms from the blood of mice infected with Trypanosoma cruzi (Y strain) were kindly provided by Dr. Mirian Cláudia de Souza Pereira, head of the Cellular Ultrastructure Laboratory (Oswaldo Cruz Foundation-Rio de Janeiro, RJ, Brazil), and were used to obtain the different evolutive stages of the parasite for the tests performed [24].

The metacyclic trypomastigotes of T. cruzi were obtained from cultures of LLCMK2 cells. After growth, the culture medium was discharged, and the cells were washed with phosphate-saline buffer (PBS). Then, the cells were trypsinized by incubation for 5 to 10 minutes at 37°C.
with a solution containing 1 mM ethylene diamino tetraacetic acid (Merck KGaA, Darmstadt, Germany) and 0.25% trypsin (Life Technologies) in PBS. The incubation was interrupted by the addition of PBS supplemented with 10% SFB, followed by centrifugation at 1500 rpm, for 6 minutes, at 20°C. The cells were resuspended in dilution from 1:5 to 1:10 in complete RPMI medium (Merck KGaA, Darmstadt, Germany). When the culture reached about 50% confluence, LLCMK2 cells were infected with the trypomastigotes of the \textit{T. cruzi}, Y strain in a ratio of 5 to 10 parasites per cell. After 24 hours, non-internalized parasites were removed. The trypomastigotes used were obtained from the collection of LLCMK2 cell supernatant, on the 7th and 9th days after infection. LLCMK2 adherent epithelial cell lines were maintained in complete RPMI 1640 (Merck KGaA, Darmstadt, Germany) medium (2 mM glutamine, 50 mM β-mercaptoethanol, 100 mM pyruvate, 50 μg.mL⁻¹ of gentamicin, non-essential amino acids, supplemented with 2.5% SFB), at 37°C with a humid atmosphere containing 5% CO₂. All experiments were conducted with biosafety level 2.

\textbf{Epimastigote growth.} The epimastigotes of \textit{T. cruzi} were grown in cardiac and brain tissue infusion medium (BHI, BD Bioscience) supplemented with 10% fetal bovine serum (SFB, Gibco), 20 μg.mL⁻¹ of folic acid (Merck KGaA, Darmstadt, Germany), 12 μg.mL⁻¹ of hemin (Merck KGaA, Darmstadt, Germany), 10 μg.mL⁻¹ of gentamicin (Merck KGaA, Darmstadt, Germany), this medium being called complete BHI. The parasite cultures were kept in a BOD incubator at 27°C, passing every 7 days, using inoculum of 10⁶ parasites.mL⁻¹ in 25 mL of complete BHI medium. The parasites were centrifuged at 2200 rpm for 10 minutes at 4°C, resuspended in 10 mL of complete BHI and quantified in a Neubauer chamber with 0.01% trypan blue (Riedel-de Haén, North Carolina, USA). The epimastigote forms used in the tests were fifth pass at most.

\textbf{Peritoneal macrophages.} Macrophages were obtained from BALB/c mice by washing the peritoneal cavity with 5 mL of DMEM (Gibco-Invitrogen) supplemented and without serum. For duplicate assays, cells were taken from the peritoneal lavage of 6 animals. The cells were counted in a Neubauer chamber using trypan blue (Merck KGaA, Darmstadt, Germany). Cell concentration was adjusted to 2x10⁵ cells.mL⁻¹ in supplemented DMEM medium with 10% SFB. Then, 1 mL of this suspension was distributed in triplicates in microplates of 24 and 48 wells for cell culture (TPP). The plates were incubated at 37°C under 5% CO₂, for 3 hours.

\textbf{Cytotoxicity assays.} Cell toxicity was assessed using the XTT colorimetric method \cite{25,26}. The test was performed in the presence of the PMS electron acceptor. The peritoneal macrophages of BALB/c mice were cultured in 96-well microplates, with complete DMEM culture medium (10⁵ cells per well), maintained under the same experimental conditions as a control of the technique. The macrophages were then incubated with nimesulide at concentrations of 17 and 35 μM for 24 and 48 hours. After incubation, 50 μL of XTT solution (1.8 mg of XTT, 75 μL of PMS and 1.425 μL of PBS) were added to each well. After 48 h the reading was performed in a microplate reader equipped with a 490 nm filter (Spectramax M3).

\textbf{Viability of \textit{T. cruzi} epimastigotes treated with different concentrations of nimesulide.} \textit{T. cruzi} epimastigotes in exponential growth phase (96 h) were resuspended in complete BHI medium at the final concentration of 2.0 x 10⁵ parasitemL⁻¹. In 96-well culture microplates, 100 μL of the parasite culture were added and were treated or not with different concentrations of nimesulide ranging from 100 to 1.56 μM. The plates were incubated at 27°C for 72 hours in BOD. The MTT reduction assay was performed in order to analyze the viability of the parasites in each treatment \cite{27}. The trypanocidal effect was assessed by the concentration of nimesulide required for 50% inhibition of epimastigotes growth (IC₅₀) when compared to untreated control. Benznidazole was used as positive control.

\textbf{Infection of macrophages with trypomastigotes.} During the parasitic peaks, supernatant from infected LLCMK2 cells was centrifuged to obtain \textit{T. cruzi} trypomastigotes. Then, the
Parasites were resuspended in complete RPMI medium, reaching a concentration of 1.0 × 10^7 parasites mL^{-1}. The macrophages were infected in the ratio of 3 trypomastigotes per cell. The culture was at 37°C with a humid atmosphere containing 5% CO_2. After 24 hours the wells were washed with PBS and maintained in complete DMEM, in the presence or not of nimesulide and 35 μM benznidazole and kept at 37°C with a humid atmosphere containing 5% CO_2 for ten days. The parasites growth was evaluated after seven and nine days in culture, by counting in Neubauer’s chamber the free trypomastigote released.

**Assessment of parasites viability by flow cytometry.** Epimastigotes of *T. cruzi* (1.0 x 10^6 parasites mL^{-1}) were incubated with 35 μM nimesulide for 24 hours. After treatment, they were centrifuged and resuspended in 1000 μL of buffer. The suspension was centrifuged again and then treated with annexin V-FITC (AV) and propidium iodide (IP) for analysis in flow cytometer (FACSCALIBUR Becton & Dickinson).

**Ultrastructural analysis.** Epimastigotes of *T. cruzi* (2 x 10^5 parasites mL^{-1}) of third passage, in the exponential growth phase, were treated or not with 35 μM nimesulide for 24 hours and fixed with 2.5% glutaraldehyde, diluted in 0.1 M sodium cacodylate, containing 3.5% sucrose. The medium was kept under pH 7.2 and 4°C for 1 hour. Then, the parasites were washed in the same buffer and post-fixed with 1% osmium tetroxide diluted in 0.1 M sodium cacodylate buffer at pH 7.2 and 4°C for 1 h. Then, the cells were washed in the same buffer, dehydrated in acetone gradient (30%, 50%, 70%, 90% and 100%) and incorporated in PolyBed 812 resin. After polymerization, ultrafine sections were obtained in Leica ULTRACUT S UCT (Leica Microsystems’ Instruments, Wetzlar, Germany) contrasted with 5% uranyl acetate and, afterwards, with 1% lead citrate. The analysis was performed using a transmission electron microscope (Jeol JEM-1011; Tokyo, Japan) at the Rudolf Barth Electron Microscopy Platform (Fiocruz-Rio de Janeiro, Brazil).

**Statistical analysis.** To assess the effect of nimesulide on the growth of parasites the data were analysed by the GraphPad Prism version 6 program, in one-way ANOVA analysis tests for independent samples, followed by Dunnet’s “t” test. The significance values were represented in the graphs by (•) for values with p <0.05; (••) for values with p <0.01 and (•••) for values with p <0.001.

**Results**

**Chemistry**

The purity grade of nimesulide extracted from the commercial medicine (≥98%) was determined by RP-HPLC (S7 Fig).

As shown in Fig 1B, in order to evaluate the role of nitroaromatic moiety of nimesulide structure, the aniline 4 was synthesized through a chemoselective reduction of the nimesulide’s nitro group in presence of metallic iron in mild acidic medium (aqueous NH_4Cl) [22, 23]. This methodology furnished the amine 4 without touching other groups present in drug structure, such as the sulfonylanilide moiety. The reduction product had its degree of purity (≥ 98%) evaluated by HPLC (S8 Fig) previously to the biological evaluations.

**Biological assessments**

**Characterization of the cytotoxic effect of nimesulide under experimental conditions.** The experiment was conducted with the aim to infer whether the concentrations of nimesulide used in the treatments of epimastigotes would impair mammalian cell viability. The assay was conducted by incubating peritoneal macrophages of BALB/c mice with two concentrations of nimesulide, under the same experimental conditions used to epimastigotes. The results obtained showed that nimesulide does not have any toxic effects against murine macrophages,
even at the highest concentration evaluated. Nimesulide was less toxic to murine macrophages than benzonidazole, as shown in Fig 2A.

Cell viability of *T. cruzi* (Y strain) epimastigotes treated with nimesulide. After treatment of epimastigotes with nimesulide (3), in concentrations ranging from 2.0 to 100 μM, cell death was observed in a dose-dependent manner, allowing the calculation of the inhibitory concentration for 50% of the epimastigote forms (IC₅₀ = 12.93 ± 0.03 μM). No toxic effects on the parasites were observed at concentrations of less than 1 micromolar. In the same conditions benznidazole (used as control drug) showed IC₅₀ = 3.82 ± 0.65 μM. However, when epimastigotes were treated in the same conditions with the chemically reduced aniline (4) no cell death was observed (IC₅₀ > 200 μM). A control assay with DMSO (solvent used in the dilutions) was done under the same conditions, showing no toxicity in the concentrations used. The results are shown in Fig 2B.

Nimesulide reduces *T. cruzi* replication in macrophages. The treatment of peritoneal macrophages from BALB/c mice infected with *T. cruzi* trypomastigotes with nimesulide resulted in inhibition of intracellular amastigote replication, as shown in Fig 3A. It was observed a reduction in the number of viable trypomastigotes in the supernatant in the days 7 and 9 after infection, according to Fig 3B.

Assessment of parasites viability by flow cytometry. The analysis of parasites treated for 24 hours with nimesulide revealed staining for both probes, IP and AV. The results confirmed that treatment was like that of benznidazole, under the same conditions (Fig 4A and 4B).

Ultrastructural assessment of the effects of the drug nimesulide on *T. cruzi* epimastigotes in transmission electron microscopy. In order to observe whether the treatment with nimesulide caused ultrastructural effects on the parasites, epimastigotes forms (Y strain) were treated or not with 35 μM nimesulide for 24 h. After the incubation, processing for transmission electron microscopy was performed and the material analysed indicated significant changes in cell organelles. The epimastigote cells in axenic culture revealed a characteristic organization of this evolutive form (Fig 5A). However, a close view of the parasites treated with nimesulide (3) indicated generalized changes (Fig 5B). Futhermore, untreated parasites showed intact mitochondria containing the kinetoplast, nucleus and preserved reservosomes (Fig 5C). Although, in the treated forms, the mitochondria appear with changes in its structure, quite dilated and without apparent ridges, containing the electron-dense, well-compacted kDNA, with exacerbated condensation, indicating a possible alteration in the architecture of the genetic material (Fig 5D).

In addition, it was possible to highlight the presence of acidocalcisome in untreated parasites (Fig 6A), but treated parasites shows sections of the nuclear envelope adhered heterochromatin and cytosol it was possible to identify myelin figures (Fig 6B and 6C).

In general, the micrographs of the untreated parasites showed a characteristic mitochondrial profile, close to the plasma membrane, kinetoplast with kDNA preserved in the mitochondrial portion between the nucleus and the flagellum (Fig 6D). On the other hand, after incubation with nimesulide, mitochondria were well dilated, with loss of crests throughout the body of the parasites, electron-dense kinetoplast and presence of reservosomes with low content (Fig 6E and 6F). Thus, the analysis of electron micrographs showed that nimesulide caused important ultrastructural changes on *T. cruzi* epimastigotes.

Discussion

The search for new molecules that have effective and safe activity against *T. cruzi* has motivated a series of studies in several research groups. Chagas disease is a public health problem [1] and the therapeutic action of the two drugs available to treat infected patients are benznidazole and...
nifurtimox which has severe limitations mainly in the chronic phase of the infection [28]. Several compounds were tested in order to identify their activity, including those from the class of nitroaromatics [29]. Indeed, interest in molecules containing the nitro group has undergone a resurgence in recent years, due to a greater understanding of the role of nitro-reductases involved in their activation and also on the mechanisms by which parasites develop resistance [30]. Our goal was to evaluate the ability of the nitroaromatic drug nimesulide to inhibit the growth of the different evolutive forms of \textit{T. cruzi}, in an attempt to propose the repositioning of this drug for the treatment of Chagas disease. The process of discovering other therapeutic purposes for commercialized drugs brings significant savings in time and costs [5]. This approach is particularly attractive when applied to neglected diseases, since there are no significant investments in the development of new drugs in this field [31]. Our results pointed to the trypanocidal activity of nimesulide on \textit{T. cruzi} epimastigotes. Interestingly, the trypanocidal activity shown by nimesulide disappeared after the chemoselective reduction of the nitro group present in its molecule, that stimulated us to study the role of the nitro group as the

Fig 2. A. Cytotoxicity assay. Peritoneal macrophages of BALB/c mice incubated with benznidazole and nimesulide, at concentrations of 17 and 35 μM. Representative results from two independent experiments. B. Cell viability of \textit{T. cruzi} epimastigotes (Y strain) in different concentrations of NIM and BNZ. Treatment after 48 hours of incubation at 27˚C. In this assay, the inhibitory concentration (IC\textsubscript{50}) of nimesulide against epimastigotes was 12.93 ± 0.03 μM, and for benznidazole 3.82 ± 0.65 μM. Both results were for two independent experiments. Asterisks represent the significant difference from the untreated control (\(p<0.05\)).

https://doi.org/10.1371/journal.pone.0258292.g002

nifurtimox which has severe limitations mainly in the chronic phase of the infection [28]. Several compounds were tested in order to identify their activity, including those from the class of nitroaromatics [29]. Indeed, interest in molecules containing the nitro group has undergone a resurgence in recent years, due to a greater understanding of the role of nitro-reductases involved in their activation and also on the mechanisms by which parasites develop resistance [30]. Our goal was to evaluate the ability of the nitroaromatic drug nimesulide to inhibit the growth of the different evolutive forms of \textit{T. cruzi}, in an attempt to propose the repositioning of this drug for the treatment of Chagas disease. The process of discovering other therapeutic purposes for commercialized drugs brings significant savings in time and costs [5]. This approach is particularly attractive when applied to neglected diseases, since there are no significant investments in the development of new drugs in this field [31]. Our results pointed to the trypanocidal activity of nimesulide on \textit{T. cruzi} epimastigotes. Interestingly, the trypanocidal activity shown by nimesulide disappeared after the chemoselective reduction of the nitro group present in its molecule, that stimulated us to study the role of the nitro group as the

Fig 3. Infection of peritoneal macrophages in BALB/c mice with trypomastigotes, followed by treatment with benznidazole and nimesulide. A. Inhibition of amastigotes after 3 days of treatment. B. Release of trypomastigotes after 7 and 9 days of treatment. Representative results from two independent experiments. Both results were for two independent experiments. Asterisks represent the significant difference from the untreated control (\(p<0.05\)).

https://doi.org/10.1371/journal.pone.0258292.g003
possible pharmacophore for the trypanocidal activity observed to nimesulide. In addition, tests carried out against the other evolutive forms of the parasite revealed that nimesulide inhibited both the replication of amastigotes and the release of trypomastigote forms when comparing to benznidazole. In addition, the results of flow cytometry tests indicated that after 24 hours of treatment nimesulide shows toxic effects on T. cruzi like benznidazole. The positive marking for both probes (Annexin-V/PI staining) used to distinguish the different ways of cell death showed that nimesulide induced two simultaneous mechanisms of parasite death by necrosis and apoptosis. These results are in complete agreement to those shown by Tay and co-workers [32]. In this study, the group showed the effects of nimesulide on isolated mouse liver mitochondria which experienced both uncoupling as calcium-dependent membrane permeability transition (MPT). These events led to the increase in mitochondrial oxidative stress. Another important result highlighted by the authors shows that the corresponding amine (obtained by chemoselective reduction of nitro group of nimesulide) does not provide the same mitochondrial effects. In fact, the authors describe a protective effect promoted by amine against ROS production [32]. These results corroborate our findings on the effects of both compounds (nimesulide and its corresponding amine) on T. cruzi epimastigote cells. It is well known in the literature that this kind of deleterious effects in mitochondria induces cell death by mixed mechanisms, that is both by necrosis and apoptosis [33–35].

The ultrastructural organization of the different evolutive forms of T. cruzi has been extensively studied by the transmission electron microscopy (TEM) technique [36]. In Figs 5A and 5C and 6A and 6D we can see the main organelles found in the complete epimastigote form of the parasite used as a control in our work which are in full agreement with the data previously described, in the anterior region of the parasite [36–38]. Epimastigotes of T. cruzi have a
spherical nucleus and nuclear envelope with pores, and a nucleolus in the central portion. The flagellum protrudes from the half of the protozoan’s body. The kinetoplast, a specific region of the mitochondria in which the DNA is concentrated, has a disk shape [15, 36, 37]. The shape of the kinetoplast and its position in relation to the nucleus are characteristic in the different evolutive forms of *T. cruzi*, and in epimastigotes it is found between the flagellar pocket and the nucleus, in the anterior region of the parasite [36, 37].

Herein the TEM analysis of epimastigotes maintained in axenic culture revealed the integrity of the parasite, when compared to the literature [15, 36]. All the characteristics could be observed in the obtained micrographs, as shown in Figs 5A and 5C and 6A and 6D. In turn, *T. cruzi* epimastigotes treated with nimesulide demonstrated important ultrastructural changes, mainly in the loss of mitochondrial membrane morphology and strong kinetoplast compaction. Mitochondrial changes are common in both necrosis and apoptosis, and in the case of necrosis, a concomitant increase in cytoplasmic vacuolization is observed [17]. The increase in cytoplasmic vacuolization was also observed in our study. Data from literature demonstrate that reservosomes play an important role in the integrity of *T. cruzi* epimastigotes affecting parasite’s lipidic metabolism which is impaired or may even start a proteolytic process, resulting in cell death [17]. In the present study, we observed that the treatment of epimastigotes with nimesulide caused a clear disorganization of epimastigote’s reservosomes, pointing to an
Fig 6. Effects of nimesulide on T. cruzi. A: Calciosomal acids distributed in the cytoplasm, indicated by arrowheads and intact nucleus (N), in the untreated control. After treatment with nimesulide, B: Nucleus (N) with disruption of the nuclear envelope, dilated mitochondria (M) and presence of vacuoles, and C: Disorganized nucleus (N) with heterochromatin adhered to some sections of the nuclear envelope (straight arrows), figures of myelin are present in the cytosol, represented by the arrowhead. D: Well-preserved mitochondrial profile, close to the plasma membrane, the kinetoplast (K) also shows the kDNA preserved in the mitochondrial portion between the nucleus (N) and the flagellum (F), in the untreated control. After treatment with nimesulide, E: The treatment induced profound alterations on nuclear morphology (N) and kinetoplast condensation (K), and F: Mitochondria (M) well dilated and with loss of ridges throughout the parasite body, electrodense kinetoplast (K) and presence of the reservosomes (R) with low content.

https://doi.org/10.1371/journal.pone.0258292.g006
imbalance in the parasite’s metabolism. Another ultrastructural aspect found in our study was
the abnormal pattern of heterochromatin distribution in the treated epimastigotes indicating
the damage caused by nimesulide in this organelle in a process suggestive of apoptosis [18].
Thus, we were led to believe that the ultrastructural effects observed after treatment with nimesu-
lide point to cell death due both to apoptosis and necrosis.

An important and advantageous aspect to be considered about the repositioning of nimesu-
lide for the treatment of Chagas disease patients is that inflammatory processes are among
the most harmful effects caused by parasites in the chronic phase of the infection. Persistent car-
diac tissue parasitism causes serious inflammatory complications, causing irreversible myocar-
dial damage [38]. In this sense, the use of an anti-inflammatory drug can be advantageous to
alleviate the inflammatory damage caused to patients in the chronic phase of the disease.

In general, the different methodological approaches, involving repositioning, consider as an
important aspect the fact that the effectiveness of the candidate drug is associate with the mini-
mization of side effects to the patient. In addition, many studies compare the results observed
in monotherapy with combination with another drug. For example, Guedes-da-Silva and co-
workers [39] investigated the effectiveness of oral doses of the experimental 14α-demethylase
inhibitor, VNF, both in monotherapy as in combination with BNZ in infected mouse. All tested
mice groups resulted in >99.9% of parasitemia decrease and 100% animal survival. In another
recent study, the antibiotic Clofazimine and the antihypertensive Benidipine were evaluated by
in combination with low doses of Benznidazole against the intracellular amastigotes of T. cruzi
both in vitro and in a murine model of chronic infection with promising results [40]. In present
in vitro study, we tested nimesulide against Trypanosoma cruzi and showed its toxic action on
different evolutive forms of the parasite. The results obtained herein open a perspective to a
future study on the effects of the association of nimesulide and benznidazole, both in vitro as in
vivo. Another point to be highlighted is the existence of Trypanosoma cruzi strains resistant to
benznidazole. Although we observed nimesulide shows IC_{50} values higher than benznidazole,
the perspective of the antiparasitic action of this NSAID in benznidazole resistant strains may
bring benefits to the chagasic patients enabling a more effective treatment. Furthermore, the
treatment with the association of the two drugs in reduced doses could be shorter, more effec-
tive, and safer. A similar study was carried out by Torrico et al. [41] who found that the combi-
nation of benznidazole and fosravuconazole reduced the treatment time, which improved
patient compliance due to the minor side effects produced. Further studies regarding the safety
of using nimesulide in the treatment of chagasic patients should consider that the most impor-
tant adverse effects observed for nimesulide, and also for other nitroaromatic drugs, involve
liver damage. However, at the recommended therapeutic doses, these effects are associated with
issues of idiosyncrasies and individual predispositions [42]. Furthermore, many of the problems
are associated with the use of the drug without professional supervision and with its easy acquisi-
tion without a prescription. Finally, it should be noted that pharmacokinetic studies available
for nimesulide indicate the drug reaches an average plasma concentration of 39.15 μM, in a
period of 3.19 h [43], when administered in an oral dose of 200 mg, which is a safe dose when
using nimesulide as anti-inflammatory drug. Although the high affinity of nimesulide for
serum proteins, mainly albumin, is well described in the literature [44], the plasma concentra-
tions of nimesulide described by Kim and co-workers [43] are close, and even higher, to the
effective trypanocidal concentrations of nimesulide assayed in this work.

In conclusion, the set of results obtained in this work shows the potential of nimesulide to
be repositioned as an anti-Chagas drug or yet to serve as a starting point for the design of a
new class of antichagasic analogs. The results obtained herein shows that nimesulide drug has
remarkable effects on the different evolutive forms of T. cruzi. It was demonstrated that the
antiparasitic effects of the drug are related to the nitro group present in its structure, since the
aniline derivative, obtained by chemoselective reduction of nimesulide was not active. The data obtained in this study, when compared to those previously described in the literature, suggest the interference of nimesulide in the redox balance of the parasite’s cell, promoting its death mainly by oxidative stress. It was found that epimastigotes treated with nimesulide follow mixed mechanisms of death, due both to apoptosis and necrosis, which correlates with the ultrastructural changes observed.

Supporting information

S1 Text. Analytical equipment used in the characterizations and determination of purity grades of compounds.
(DOCX)

S1 Fig. NMR $^1$H spectrum of nimesulide in CDCl$_3$ at 500 MHz.
(DOCX)

S2 Fig. $^{13}$C NMR spectrum of nimesulide in CDCl$_3$ at 125 MHz.
(DOCX)

S3 Fig. Mass spectrum of nimesulide.
(DOCX)

S4 Fig. RP-HPLC of nimesulide.
(DOCX)

S5 Fig. NMR $^1$H spectrum of reduced nimesulide in CDCl$_3$ at 500 MHz.
(DOCX)

S6 Fig. $^{13}$C NMR spectrum of reduced nimesulide in CDCl$_3$ at 125 MHz.
(DOCX)

S7 Fig. Mass spectrum of reduced nimesulide.
(DOCX)

S8 Fig. RP-HPLC of reduced nimesulide.
(DOCX)

S1 Table. $^1$H NMR and $^{13}$C NMR data of nimesulide.
(DOCX)

S2 Table. $^1$H and $^{13}$C NMR data of reduced nimesulide.
(DOCX)

Acknowledgments

The authors thank the staff of the Rudolf Barth Electron Microscopy Platform-Instituto Oswaldo Cruz/Fiocruz (Rio de Janeiro, Brazil), for the excellent support in preparing the samples and acquiring the TEM images.

Author Contributions

Conceptualization: Debora Decote-Ricardo, Marco Edilson Freire de Lima.

Data curation: Célio Geraldo Freire-de-Lima, Suzana Córte-Real, Debora Decote-Ricardo.

Formal analysis: Joana D’Arc S. Trindade, Suzana Córte-Real, Debora Decote-Ricardo.
Funding acquisition: Célio Geraldo Freire-de-Lima, Marco Edilson Freire de Lima.

Investigation: Joana D’Arc S. Trindade, Suzana Córte-Real, Debora Decote-Ricardo.

Methodology: Joana D’Arc S. Trindade, Debora Decote-Ricardo.

Project administration: Debora Decote-Ricardo.

Resources: Célio Geraldo Freire-de-Lima, Suzana Córte-Real.

Supervision: Célio Geraldo Freire-de-Lima, Debora Decote-Ricardo, Marco Edilson Freire de Lima.

Validation: Joana D’Arc S. Trindade, Debora Decote-Ricardo.

Visualization: Joana D’Arc S. Trindade.

Writing – original draft: Joana D’Arc S. Trindade, Marco Edilson Freire de Lima.

Writing – review & editing: Marco Edilson Freire de Lima.

References

1. World Health Organization, Chagas disease. 2020; https://www.who.int/topics/chagas_disease/en/

2. Liu Q, Zhou X N. Preventing the transmission of American trypanosomiasis and its spread into non-endemic countries. Infect Dis Poverty. 2015; 4:60. https://doi.org/10.1186/s40249-015-0092-7 PMID: 26715535

3. Klotz S A, Schmidt JO, Dorn PL, Ivanyi C, Sullivan KR, Stevens L. Free-roaming kissing bugs, vectors of Chagas disease, feed often on humans in the Southwest. Am J Med. 2014; 127:421–426. https://doi.org/10.1016/j.ajmmed.2013.12.017 PMID: 24398362

4. D’Arce Mota DCG, Benevides-Pereira AMT, Gomes ML, De Araujo SM. Estresse e resiliência em doença de Chagas. Aletheia. 2006; 24:57–68. Available from: https://www.redalyc.org/articulo.oa?id=115013462006

5. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3:673–683. https://doi.org/10.1038/nrd1468 PMID: 15286734

6. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges, and recommendations. Nat Rev Drug Discov. 2018; 18:41–58. https://doi.org/10.1038/nrd.2018.168 PMID: 30310233

7. Trochine A, Creek DJ, Faral-Tello P, Barrett MP, Robello C. Benzimidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl Trop Dis. 2014; 8:e2844. https://doi.org/10.1371/journal.pntd.0002844 PMID: 24853684

8. Machado FS, Mukherjee S, Weiss LM, Tanowitz HB, Ashton AW. Bioactive lipids in Trypanosoma cruzi infection. Adv Parasitol. 2011; 76:1–31. https://doi.org/10.1016/B978-0-12-385895-5.00001-3 PMID: 21884885

9. Freire-de-Lima CG, Nascimento DO, Soares MB, Bozza PT, Castro-Faria-Neto HC, Mello FG, et al. Uptake of apoptotic cells drives the growth of a pathogenic tripanosome in macrophages. Nature. 2000; 403(6766):199–203. https://doi.org/10.1038/35002844 PMID: 10646605

10. Mareddy J, Suresh N, Kumar CG, Kapavarapu R, Jayasree A, Pal S. 1,2,3-triazole-nimesulide hybrid: their design, synthesis, and evaluation as potential anticancer agents. Bioorg Med Chem. 2017; 3:518–523. https://doi.org/10.1016/j.bmc.2016.12.030 PMID: 28011214

11. Uram L, Filipowicz-Rachwal A, Misiorek M, Winiarz A, Walajtys-Rode E, Wołowiec S. Synthesis and different effects of biotinylated PAMAM G3 dendrimer substituted with nimesulide in human normal fibroblasts and squamous carcinoma cells. Biomolecules. 2019; 9:437. https://doi.org/10.3390/biom9090437 PMID: 31480688

12. Rasheed S, Sánchez SS, Youssif S, Honoré SM, Choudhary M. Drug repurposing: in-vitro anti-glycation properties of 18 common drugs. PLoS ONE. 2018; 13:e0190509. https://doi.org/10.1371/journal.pone.0190509 PMID: 29300762

13. Zaidel EJ, Forsyth CJ, Novick G, Marcus R, Ribeiro ALP, Pinazo MJ, et al. COVID-19: implications for people with Chagas Disease. Glob Heart. 2020; 15(1):69. https://doi.org/10.5334/gih.891 PMID: 33150134
14. Higuchi ML, Benvenuti LA, Reis MM, Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res. 2003; 60:96–107. https://doi.org/10.1016/s0008-6363(03)00361-4 PMID: 14522411

15. Vannier-Santos MA, De Castro SL. Electron microscopy in antiparasitic chemotherapy: A (close) view to a kill. Curr Drug Targets. 2009; 10:246–260. https://doi.org/10.2174/138945009787581168 PMID: 19275561

16. Rodrigues JCF, De Souza W. Ultrastructural alterations in organelles of parasitic protozoa induced by different classes of metabolic inhibitors. Curr Pharm Des. 2008; 14:925–938. https://doi.org/10.2174/138161208784010343 PMID: 18473841

17. Menna-Barreto RFS, Salomão K, Dantas AP, Santa-Rita RM, Soares MJ, Barbosa HS, et al. Different cell death pathways induced by drugs in Trypanosoma cruzi: An ultrastructural study. J Micron. 2009; 40:157–68. https://doi.org/10.1016/j.jmicron.2008.03.003 PMID: 18849169

18. Docampo R, Lopes JN, Cruz FS, Souza W. Trypanosoma cruzi: ultrastructural and metabolic alterations of epimastigotes by beta-lapachone. Exp Parasitol. 1977; 42:142–149. https://doi.org/10.1016/0040-4204(77)90071-6 PMID: 324785

19. Gonsalves AA, Araújo CRM, Leite Filho CA, Medeiros FS. Contextualizing acid-base reactions according to Bronsted-Lowry protonic theory using propranolol and nimesulide tablets. Quim Nova. 2013; 36 (8):1236–1241. https://doi.org/10.5935/0100-40422013008000024

20. Singh A, Singh P, Kapoor VK. Nimesulide. In: Brittain HG, editor. Analytical Profiles of Drugs Substances and Excipients. Academic Press; 2001. (28):pp.197–249.

21. Nunes JHB, Nakahata DH, Lustri WR, Corbi PP, Paiva REF. The nitro-reduced metabolite of nimesulide: crystal structure, spectroscopic characterization, ESI-QTOF mass spectrometric analysis and antibacterial evaluation. In: Journal of Molecular Structure. Academic Press; 2018. (1157):pp. 469–475.

22. Maia RC, Silva LL, Mazzeu EF, Rezende CM, Doriguetto AC, et al. Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: discovery of novel N-aryl-semicolonin-4(3H)-one compounds derived from natural safrole. Bioorg Med Chem. 2009; 17:6517–6525. https://doi.org/10.1016/j.bmc.2009.08.009 PMID: 19699644

23. Percherla S, Mareddy J, Rani G, Gollapudi PV, Pal S. Chemical modifications of nimesulide. J Braz Chem Soc. 2007; 18:384–390. https://doi.org/10.1590/S0103-40422007000200021

24. Barbosa HS. Manutenção e obtenção dos diferentes estágios evolutivos em laboratório. In: Jorge TCA, Castro SL, organizers. Doença de Chagas: manual para experimentação animal. FIOCRUZ; 2000. pp. 184–191.

25. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell Viability Assays. In: Markossian S, Sittampalam GS, Grossman A, et al, editors. Assay Guidance Manual. Bethesda: National Center for Advancing Translational Sciences; 2013 [update 2016]. pp.305–336.

26. Roehm NW, Rodgers GH, Hatfield SM, Giasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Meth. 1991; 142:257–265. https://doi.org/10.1016/0022-1759(91)90114-u PMID: 1919029

27. Muelas-Serrano S, Nogal-Ruiz JJ, Gómez-Barrio A. Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. Parasitol Res. 2000; 86:999–1002. https://doi.org/10.1007/pl00008532 PMID: 11133116

28. Coura JR, Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2011; 106:642–645. PMID: 11992141

29. Docampo R, Lopes JN, Cruz FS, Souza W. Trypanosoma cruzi: ultrastructural and metabolic alterations of epimastigotes by beta-lapachone. Exp Parasitol. 1977; 42:142–149. https://doi.org/10.1016/0040-4204(77)90071-6 PMID: 324785

30. Patterson S, Fairlamb AH. Current and future prospects of nitro-compounds as drugs for Trypanosomiasis and Leishmaniasis. Curr Med Chem. 2019; 26:4454–4475. https://doi.org/10.2174/09298673256618042614352 PMID: 29701144

31. Oprea TI, Nielsen SK, Ursu O, Yang JJ, Taboureau O, Mathias SL, et al. Association drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inform. 2011; 30:100–111. https://doi.org/10.1002/minf.201100023 PMID: 22287994

32. Tay VKS, Wang AS, Leow KY, Ong MMK, Wong KP, Boelsterli UA. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med. 2005; 39:949–959. https://doi.org/10.1016/j.freeradbiomed.2005.05.013 PMID: 16140214

33. Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun. 2003; 304:463–470. https://doi.org/10.1016/s0006-291x(03)00618-1 PMID: 12729580
34. Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis. 2007; 12:835–840. https://doi.org/10.1007/s10495-006-0525-7 PMID: 17136322

35. Menna-Barreto RFS, Castro SL. The double-edged sword in pathogenic Trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics. Biomed Res Int. 2014; 614014. https://doi.org/10.1155/2014/614014 PMID: 24800243

36. de Souza W. Electron microscopy of trypanosomes: A historical review. Mem Inst Oswaldo Cruz. 2008; 103:313–325. https://doi.org/10.1590/s0074-02762008000400001 PMID: 18660983

37. Ferreira LRP, Dossin FM, Ramos TC, Freymüller E, Schenkman S. Active transcription and ultrastructural changes during Trypanosoma cruzi/metacyclogenesis. Ann Braz Acad Sci. 2008; 80:157–166. https://doi.org/10.1590/s0001-37652008000100011 PMID: 18345384

38. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med. 2008; 8(6): 510–518. https://doi.org/10.2174/156652408785748004 PMID: 18781958

39. Guedes-da-Silva FH, Batista DGJ, Da Silva CF, Pavão BP, Batista MM, Moreira OC, et al. Successful aspects of the coadministration of sterol 14α-demethylase inhibitor VFV and benznidazole in experimental mouse models of Chagas disease caused by the drug-resistant strain of Trypanosoma cruzi. ACS Infec Dis. 2019; 5:365–371. https://doi.org/10.1021/acsinfecdis.8b00253 PMID: 30625275

40. Sbaraglini ML, Bellera CL, Braghini JQ, Areco Y, Miranda C, Carrillo C, et al. Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease. Eur. J. Med. Chem. 2019; 184:e111778. https://doi.org/10.1016/j.ejmech.2019.111778 PMID: 31630056

41. Torrico F, Gascón J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BEND-ITA): a phase 2, double-blind, randomized trial. Lancet Infect Dis. 2021; Available from: https://doi.org/10.1016/S1473-3099(20)30844-6 PMID: 33836161

42. Boelsterli UA, Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. International Journal of Clinical practice. Supplement. 2002; 128:30–36. PMID: 12166617.

43. Kim MS, Park YS, Kim SH, Kim SY, Lee MH, Kim YH, et al. Quantification of nimesulide in human plasma by high-performance liquid chromatography with ultraviolet detector (HPLC-UV): application to pharmacokinetic studies in 28 healthy Korean subjects. J Chromatogr Sci. 2012; 50:396–400. https://doi.org/10.1093/chromsci/bms014 PMID: 22451531

44. Bernareggia A, Rainsford KD. Pharmacokinetics of Nimesulide. In: Rainsford KD, editor. Nimesulide—Actions and Uses. Birkhäuser Basel; 2005. pp. 63–120.